| abstract |
FAK INHIBITOR AND DRUG COMBINATION THEREOF.nThe invention relates to a deuterated compound as represented by formula (I)nnor an optical isomer, a tautomer, a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate thereof. Compared with a compound before deuteration, the deuterated compound shows better pharmacokinetics, higher peak plasma drug concentration, higher exposure and longer half-life, and has more excellent metabolic performance. In addition, the deuterated compound can effectively inhibit FAK activity, and it has good expectation of application in the preparation of FAK inhibitors and/or drugs for cancer treatment. Furthermore, the use of the deuterated compound in combination with an anticancer drug (such as a PD-1 inhibitor) can achieve a synergistic effect, thereby significantly improving the tumor suppression effect, and providing a better choice for clinical treatment. of cancer. |